Sign Up
Stories
Amneal Resubmits IPX203 for Parkinson’s Disease
Share
Advancements in Cancer Treatment and Mar...
Advancements in Huntington's Disease Tre...
Advancements in Psychiatric Treatments
AMX0035 for PSP: Phase 3 Trial Commences
ANJESO Drug Insight and Market Forecast
ARMGO Pharma's Positive Trial Results
Overview
API
Amneal Pharmaceuticals, Inc. resubmits a Complete Response to the FDA for IPX203, an oral formulation for Parkinson’s disease, aiming for a 2024 launch.
Ask a question
How might the potential launch of IPX203 impact the pharmaceutical industry's approach to managing Parkinson’s disease?
In what ways could the resubmission of IPX203 influence the regulatory landscape for future pharmaceutical innovations?
What are the potential implications of Amneal Pharmaceuticals, Inc.'s diverse pharmaceutical portfolio on the healthcare market?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage